Using this system, the group identified the following targets for optimal development in FGS of CRC: human carcinoembryonic antigen (CEA), CXC chemokine receptor 4 (CXCR4), epidermal growth factor receptor (EGFR), epithelial cell adhesion molecule (EpCAM), matrix metalloproteases 1, 2, 3, 7, and 9 (MMPs), Muc 1, and vascular epithelial growth factor-A (VEGF-A). This evidence concerns the gene VEGFA and colorectal carcinoma.